Inside Moderna’s Biggest mRNA Test Since COVID
Moderna has achieved a historic breakthrough with its personalized mRNA cancer vaccine (mRNA-4157/V940), demonstrating superior recurrence-free survival compared to Keytruda alone in a Phase 3 melanoma trial.summaryModerna's mRNA cancer vaccine (mRNA-4157/V940) combined with Merck's Keytruda achieved a primary endpoint of recurrence-free survival in a Phase 3 melanoma trial, marking the first time a cancer vaccine has shown efficactakeawayThe technology uses a personalized approach: sequencing both tumor and healthy DNA to identify unique mutations, then using an algorithm to select the 34 most relevant neoantigens to create a custom mRNA vaccine for eachtakeaway














